- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02305147
Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease (ICEBERG)
Etude Des Facteurs prédictifs de l'Apparition et de l'évolution de la Maladie de Parkinson
Observational, prospective, monocentric study to assess clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients and rate of progression compared to healthy controls (HC) and subjects at risk to develop PD.
The primary objective of this study is to identify clinical, imaging and biologic markers of PD onset and progression for use in clinical trials of disease-modifying therapies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ICEBERG will be a four-year natural history study of de novo idiopathic PD patients, healthy controls, and subjects at risk to develop PD (idiopathic Rem Behavior Disorder -iRBD, and probants of patients with PD genetically confirmed).
All subjects will be comprehensively assessed at baseline and every year thereafter. Subjects will undergo clinical (motor, neuropsychiatric, sleep, ocular and cognitive evaluations) and imaging assessments. Blood (including a DNA sample), stools, skin biopsy and cerebral spinal fluid (CSF) samples will be collected.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marie VIDAILHET, PhD
- Email: marie.vidailhet@psl.aphp.fr
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Hôpital Pitié-Salpétrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All subjects: Male or female age 18 years and older, MMSE score > 26, negative pregnancy test in potentially child-bearing women (contraindication to SPECT with DatScan).
- Idiopathic Parkinson disease subjects: diagnosis confirmed according to UK Parkinson's Disease Society Brain Bank criteria (UKPDSBB); disease duration less than 3 years.
- Genetic Parkinson disease subjects: parkinson diagnosis confirmed and mutation in parkin, LRRK2, SNCA or GBA genes.
- Prodromal subjects: subjects with identified relative with PD genetically confirmed or subjects with diagnosis of idiopathic Rem sleep Behavior Disorder (iRBD); neurological examination normal (no signs of parkinsonism).
- Healthy subjects: neurological examination normal
Exclusion Criteria:
- All subjects: Psychiatric disorder or any progressive life-threatening disease, impairment precluding appropriate information and instructions given concerning participation to the study; contra-indication to MRI or SPECT scan.
- Parkinson disease subjects: no dopamine transporter deficit at SPECT scan; parkinsonism induced by neuroleptics; neuroleptics intake within 6 months; atypical parkinson syndrom (MSA, PSP, CBD...)
- Parkinson disease subjects with mutation in Parkin, LRRK2, SNCA or GBA gene: atypical parkinson disease syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy) or currently taking neuroleptics or has taken neuroleptics within 6 months of baseline or any biological anomaly.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with an idiopathic Parkinson Disease,
Patients with recent onset of Parkinson Disease: N=200
|
|
Subjects at risk of PD
Subjects at risk to develop Parkinson Disease:
|
Assessment of motor and non motor signs every 12 months.
Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
|
Controls
Healthy controls: N=50
|
Assessment of motor and non motor signs every 12 months.
Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
|
Patients with Parkinson Disease with genetic mutation
Patients with Parkinson Disease with a genetic mutation in parkin, LRRK2, SNCA or GBA (N=30)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rates of change of clinical, imaging and biomic outcomes
Time Frame: 4 years (annual visits)
|
Slopes of change of clinical, imaging and biomics compared between PD patients, subjects at risk to develop PD and healthy subjects. Identification of predictive factors of these rates of change. As examples, outcomes include: MDS-UPDRS, Mattis dementia rating scale, Non Motor Signs scale, DAT striatal uptake. |
4 years (annual visits)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical milestones in PD patients
Time Frame: 4 years (annual visits)
|
Occurence of complications such as falls, freezing, dyskinesias, motor fluctuations, cognitive impairment, dysautonomia. Identification of predictive factors of these complications. Rates of progression in sub-groups of patients defined by the presence of these complications. |
4 years (annual visits)
|
Prodromal features in subjects at risk to develop PD
Time Frame: 4 years (annual visits)
|
Prodromal features such as anosmia, dysautonomia, color vision impairment, will be evaluated at inclusion and during followup in subjects with iRBD or first-degree relatives of genetically confirmed PD patients. Frequency of these features will be compared between subjects who phenoconvert and those who don't. Relation between baseline DatSCAN binding and risk of phenoconversion will be analysed. |
4 years (annual visits)
|
Phenoconversion in subjects at risk to develop PD
Time Frame: 4 years (annual visits)
|
Phenoconversion is defined as occurence of an extrapyramidal syndrome, confirmed 12 months later. Exploratory analysis to determine whether rates of progression clinical, imaging and biomic markers may predict phenoconversion in groups of patients with iRBD or probants of patients with PD genetically confirmed. |
4 years (annual visits)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Marie VIDAILHET, PhD, Assistance Publique - Hôpitaux de Paris, FRANCE
- Study Chair: Jean-Christophe CORVOL, PhD, Assistance Publique - Hôpitaux de Paris, FRANCE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C13-74
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Clinical, biological and imaging followup
-
Institut National de la Santé Et de la Recherche...Karolinska Institutet; University Hospital, Bonn; Institut d'Investigacions Biomèdiques... and other collaboratorsCompletedParkinson's Disease | Alzheimer's DiseaseFrance, Germany, Spain, Sweden
-
Centre Hospitalier Universitaire de Saint EtienneRecruitingHaemostasis EmbolisationFrance
-
Hospices Civils de LyonUnknownBone Metastases | Thyroid Cancer
-
Hôpital le VinatierRecruiting
-
Hospices Civils de LyonCompletedPediatric ALL | Allergy, NutFrance
-
University Hospital, Strasbourg, FranceCompletedBardet-Biedl Syndrome | Orphan DiseasesFrance
-
Centre Hospitalier Universitaire de Pointe-a-PitreRecruitingAtypical ParkinsonismMartinique, French Guiana
-
University Hospital, MontpellierCompletedMajor Depressive Disorders
-
M.D. Anderson Cancer CenterRecruitingStage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8United States
-
M.D. Anderson Cancer CenterRecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States